Contract pharma research provider Ergomed (LON: ERGO) is in the top forty best AIM performers over five years with a 635% increase in the share price and it is not far from quadrupling over the past year. That means that the shares have a heady rating, but the growing market and potential for earnings enhancing acquisitions make it appear warranted.
Ergomed decided to concentrate on third-party services rather than co-development more than two years ago. Last year, two major acquisitions were made in the important North American market and management would like to further increase scale in...
